熱門資訊> 正文
CRISPR Therapeutics申请6亿美元股票发行
2025-10-16 17:49
- CRISPR Therapeutics (NASDAQ:CRSP) has filed a prospectus supplement with the U.S. SEC to sell up to $600 million worth of its common shares through Jefferies LLC, acting as its sales agent.
- The sale will take place from time to time at the company’s discretion under its existing open market sale agreement with Jefferies, first established in August 2019, and will be conducted under the firm’s shelf registration statement filed in August 2024.
More on CRISPR Therapeutics
- Crispr: Investors Waiting Patiently For In-Vivo
- Crispr Therapeutics: Why Stock Fell On Q2 Earnings, And Why We're Now Back On Track
- CRISPR Therapeutics AG (CRSP) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript
- Cathie Wood's Ark Invest weekly recap: lifts stake in Bullish and Brera, trims Roku and Tempus AI
- CRISPR Therapeutics wins new Overweight rating at J.P. Morgan on pipeline prospects
推薦文章
美股機會日報 | 金價延續跌勢！黃金股盤前續跌，哈莫尼黃金大跌超6%；Beyond Meat盤前飆漲逾80%
AI仍是焦點！一圖看懂美股「七巨頭」Q3財報前瞻
貝萊德周度投資觀點：美國企業盈利韌性仍是關鍵
AI熱潮仍在湧動！小摩：英偉達(NVDA.US)、AMD(AMD.US)和博通(AVGO.US)營收上行潛力被低估
消息稱特朗普政府計劃對全球藥品定價展開新的調查
金價大跌是什麼信號？前FED顧問：系統性「流動性危機」已至，金融體系正崩潰！
華盛早報 | 黃金遭全面拋售！一夜暴跌超5%創十二年最大單日跌幅；Beyond Meat受散户追捧，股價三日漲近6倍
德州儀器第四季度業績展望不及預期，暗示半導體行業復甦緩慢，績后股價大跌8%
風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。
